Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide versus alfacalcidol for cardiac hypertrophy in hemodialysis patients
2017-000222-35Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) comparing Etelcalcetide arm with Alfacalcidol arm (2 arms). Primary endpoint: Change in left ventricular mass index. Started Jul 2017; status: completed.
02
Drugs
etelcalcetidealfacalcidol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-000222-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000222-35.